Please ensure Javascript is enabled for purposes of website accessibility

Will Teladoc Stock Be a $200 Stock?

By Cory Renauer - May 13, 2020 at 12:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can the telehealth pioneer meet recently raised expectations?

Sandy Draper, an analyst from SunTrust has raised his bank's price target on shares of Teladoc Health (TDOC -3.62%) in response to increased utilization influenced by stay-at-home orders. Draper raised Suntrust's price target on shares of the telehealth pioneer to an even $200 from the previous target of $144 set in April. 

A 10% gain ahead?

At recent prices, SunTrust's new price target suggests a 10% gain once the market comes to the same conclusions as Draper. Teladoc's stock soared past $195 this morning but the price settled to $185 by the afternoon.

Teladoc's top line is headed in the right direction at a fast enough pace. In the first quarter, Teladoc delivered 2 million medical visits which pushed total revenue 29% higher year over year to $137 million.

A doctor on video chat

Image Source: Getty Images

In 2020, the company expects total revenue to reach between $800 million and $825 million which means the stock's currently trading at around 16.8 times sales. This is a really high multiple, but it's not that farfetched when you consider how much room Teladoc still has to grow.

Here comes the competition

Stay at home orders have inspired increased utilization of Teladoc's services, but it looks like the company's already cutting prices to boost subscriptions. Paid U.S. membership rose 61% year over year to 43 million but subscription access fee revenue rose just 33% over the same period. 

Unfortunately for Teladoc, the COVID-19 pandemic has unleashed a deluge of cash on digital health start-ups that could become tomorrow's competition. The market seems willing to overlook Teladoc's bottom line wallowing in negative territory for now, but further signs of a pricing war with similar businesses could cause investors to lose their patience.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
$39.45 (-3.62%) $-1.48
SunTrust Banks, Inc. Stock Quote
SunTrust Banks, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.